September 13th 2024
As new litigation looms in the debate over use of copay accumulator programs, a look at potential next moves for payers—and steps drug manufacturers should take to ward off cost-driven non-adherence.
Pricing Climate Impacting Commercial Considerations
May 3rd 2024In this Pharmaceutical Executive video interview, Jesse Mendelsohn, senior vice president at Model N, talks about the influence of Medicare Part D drug price negotiations on manufacturer go-to-market strategies and decision-making, and the industry’s response to the wider dialogue on pricing transparency.
Current Drug Affordability Challenges
August 2nd 2023In this exclusive Q&A, Vishali Amin, chief of staff to the office of the president and senior director of customer success for Kalderos, discusses the biggest hurdles to drug affordability, how patients can become aware of drug discounts, how drugs are selected for regulatory discount programs, and drug pricing strategies.
The Price of Innovation: ‘Paying for a Cure’ Remains Costly Proposition
August 10th 2022Curative-type therapies offer great hope in further transforming treatments for cancer and other diseases, but addressing the economics of these products—and ultimately the cost-benefit equation—is daunting. What is being done to smooth the path for pricing and reimbursement?
A Complex Patent & Pricing Picture: Regulating Psychedelics More of a Journey Than a Trip
March 8th 2022Pharma and legal experts weigh in on the rush to secure intellectual property around psychedelic medicines, the value imperative that should govern pricing strategies, and the likely long-haul battle for more widespread decriminalization of these drugs.
Drug Costs Central Issue in Budget Battles
December 7th 2021As Congress struggles to reach agreement on funding for leading social and spending initiatives and to avoid default on government borrowing, the White House is emphasizing that reduced spending on prescription drugs can help offset some of the steep costs.
Generics Makers Also Fight Price Controls
November 12th 2021The Democratic proposal to authorize price negotiations on costly medicines covered by Medicare and to penalize firms that raise prices faster than inflation has drawn opposition pharma and biotech companies. More surprisingly, generic companies also are objecting to the changes on the table.
China 2021 National Reimbursement Drug List Outlook
November 11th 2021The 2021 National Reimbursement Drug List (NRDL) process has been unfolding in China since June this year, with several key themes emerging. Building on Simon-Kucher’s experience with the NRDL, the authors make three recommendations on negotiation strategies going into the process.
Improving Readiness for Volume-Based Procurement in China
October 13th 2021Volume-based procurement (VoBP) has been gathering momentum in China, both at national and regional levels. Major pharmaceutical players stand to see large impacts on their branded generics portfolio, and need to move fast to improve organizational and system readiness.